GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals Inc (NAS:SCLN) » Definitions » Operating Margin %

SciClone Pharmaceuticals (SciClone Pharmaceuticals) Operating Margin % : 27.67% (As of Jun. 2017)


View and export this data going back to 1992. Start your Free Trial

What is SciClone Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. SciClone Pharmaceuticals's Operating Income for the three months ended in Jun. 2017 was $12.3 Mil. SciClone Pharmaceuticals's Revenue for the three months ended in Jun. 2017 was $44.5 Mil. Therefore, SciClone Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2017 was 27.67%.

The historical rank and industry rank for SciClone Pharmaceuticals's Operating Margin % or its related term are showing as below:


SCLN's Operating Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.075
* Ranked among companies with meaningful Operating Margin % only.

SciClone Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

SciClone Pharmaceuticals's Operating Income for the three months ended in Jun. 2017 was $12.3 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2017 was $44.4 Mil.


SciClone Pharmaceuticals Operating Margin % Historical Data

The historical data trend for SciClone Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals Operating Margin % Chart

SciClone Pharmaceuticals Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.10 8.21 19.28 19.02 20.76

SciClone Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.27 25.78 16.81 33.19 27.67

Competitive Comparison of SciClone Pharmaceuticals's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SciClone Pharmaceuticals's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where SciClone Pharmaceuticals's Operating Margin % falls into.



SciClone Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

SciClone Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2016 is calculated as

Operating Margin %=Operating Income (A: Dec. 2016 ) / Revenue (A: Dec. 2016 )
=33.235 / 160.096
=20.76 %

SciClone Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2017 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2017 ) / Revenue (Q: Jun. 2017 )
=12.317 / 44.52
=27.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SciClone Pharmaceuticals  (NAS:SCLN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


SciClone Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


SciClone Pharmaceuticals (SciClone Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
SciClone Pharmaceuticals Inc is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders.
Executives
Richard J Hawkins director 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Nancy T Chang director 101 WESTCOTT, SUITE 603, HOUSTON TX 77007
Raymond Anthony Low director, officer: VP, Finance & Controller 25 SHADOW TREE CT, DANVILLE CA 94506
Wilson Wai-shun Cheung officer: CFO & Senior VP, Finance SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Jon S Saxe director FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Robert King officer: SVP of Prod. Dev/Supply Chain 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Winnie Wing-kei Tso other: VP, Finance and Controller 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Stephanie Wong officer: VP, Finance and Controller 343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080
Gary Titus officer: Senior VP Finance & CFO SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Peter Barrett director C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Paolo Cavazza 10 percent owner VIA TESSERETE, 10, LUGANO V8 V8
Farmaceutica Lda Defiante 10 percent owner RUA DOS FERREIROS,260, FUNCHAL MADEIRA S1 9000-082
Dean S Woodman director 233 MOCKINGBIRD TRAIL, PALM BEACH FL 33480